Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Product Development

Rare disease spotlight: a leukodystrophy with small pipeline behind first approval

At least three MLD programs are coming up behind Orchard’s Lenmeldy, although three others were recently discontinued

April 18, 2024 12:29 AM UTC

As U.S. patients with metachromatic leukodystrophy begin to get access to the first approved therapy for the rare disease, the pipeline coming up behind Orchard’s Lenmeldy is shrinking.

At least three programs were recently discontinued for metachromatic leukodystrophy (MLD), reducing the disclosed pipeline by half. Two of the three remaining companies still developing a program for the indication are preclinical, while the one clinical company is seeking out-licensing opportunities for its Phase I/II asset. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article